Experimental shot aims to clear stubborn HPV infection in the anal region

NCT ID NCT07710664

Recruiting now Disease control Sponsor: Newish Biotech (Wuxi) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This early-stage trial tests an experimental therapy called NWRD09 in 10 adults aged 18 to 60 who have had a persistent HPV16 infection in the anal area for at least a year. The therapy is given as an injection and is designed to help the body clear the virus. The study primarily checks whether the treatment is safe, and also looks at whether it can eliminate the virus by weeks 16 and 28.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental vaccine-like therapy called NWRD09
What this could lead to: If successful, this could point toward a treatment that clears persistent HPV16 infections, potentially reducing the risk of anal cancer.
What could go wrong: This is a very early, small study with only 10 participants, so results may not apply broadly. The main goal is safety, and the therapy may not effectively clear the virus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates